Xiansheng Pharmaceutical’s Innovative Brain Cell Protection Drug Approved for Market
December 4, 2024
Source: drugdu
31
On December 1, Xiansheng Pharmaceutical's innovative brain cell protection drug, Xianbixin sublingual tablets, was approved for market launch. Xianbixin is a dual-target brain cell protector that contains two active ingredients: Edaravone and R-(-)-Borneol. These ingredients work synergistically to enhance both antioxidant and anti-inflammatory effects, significantly reducing brain cell damage caused by acute ischemic stroke. In 2020, Xiansheng Pharmaceutical launched a Class 1 innovative drug, Xianbixin (in injectable form) in China, making it the only innovative drug approved in the stroke field globally in nearly a decade.
https://finance.eastmoney.com/a/202412023256274687.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- 1 medical device enters the priority approval green channel December 4, 2024
- Artificial cochlear implant leader, impacting IPO! December 4, 2024
- Three giants of IL-23, “making a big splash” in the ulcerative colitis market December 4, 2024
- China’s bispecific antibodies compete in the multi-billion dollar race December 4, 2024
- Received Approval Notification for Clinical Trials of Adsorbed Tetanus Vaccine December 4, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
